title: Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.
abstract: Although mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate adjuvant and/or delivery system. Therefore, there is still an imperative demand for an improved, safe and efficient delivery system to enhance the immunogenicity of available vaccine candidates. Nanoparticles are proficient in boosting the quality and magnitude of immune responses in a predictable fashion. Herein, we discuss how nanoparticulate vaccine delivery systems can be used to induce appropriate immune responses against leishmaniasis by controlling physicochemical properties of the vaccine. Stability, production reproducibility, low cost per dose and low risk-benefit ratios are desirable characteristics of an ideal vaccine formulation and solid lipid nanoparticles may serve as one of the most promising practical strategies to help to achieve such a leishmanial vaccine, at least in canine species in the developing world.
authors.affiliation: Quality Control Department, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Delaram
authors.initials: D
authors.lastname: Doroud
authors.forename: Sima
authors.initials: S
authors.lastname: Rafati
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D007891:Leishmania / Q000276:immunology / Q000472:pathogenicity; D007896:Leishmaniasis / Q000276:immunology* / Q000517:prevention & control*; D054332:Leishmaniasis Vaccines / Q000008:administration & dosage / Q000276:immunology*; D053758:Nanoparticles / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D054332:Leishmaniasis Vaccines